ReviewPediatric nephrology (Berlin, Germany)2022
Anti-glomerular basement membrane disease in children: a brief overview.
Review in Pediatric nephrology (Berlin, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- Pediatric anti-GBM crescentic glomerulonephritis: partial renal recovery following plasmapheresis and mycophenolate mofetil.CEN case reports · 2026Article
- Anti-glomerular basement membrane nephritis following IgA vasculitis in a child: a diagnostic challenge.Pediatric nephrology (Berlin, Germany) · 2026Article
- Anti-glomerular basement membrane disease-treatment standard.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Review
- Efficacy and Safety of Rituximab in Antiglomerular Basement Membrane Disease.Kidney international reports · 2025Article
- Outcome of rituximab treatment in children with non-dialysis-dependent anti-GBM disease.Pediatric nephrology (Berlin, Germany) · 2025Article
- Atypical Anti-glomerular Basement Membrane Disease in a 16-Year-Old Male Child: A Case Report.Cureus · 2025Article
- Complement in anti-glomerular basement membrane glomerulonephritis.Frontiers in immunology · 2025Review
- Article
- Article
- Pediatric double-seropositive anti-glomerular basement membrane antibody disease: A case report and literature review.Clinical nephrology. Case studies · 2024Article
- Anti-Glomerular Basement Membrane Disease in a 10-year-old Child: A Case Report.JNMA; journal of the Nepal Medical Association · 2023Article
- Case report: A study on theFrontiers in pediatrics · 2022Article
- Anti-glomerular basement membrane disease in children: can Sars-Cov-2 be a trigger?Jornal brasileiro de nefrologiaArticle
- Mitigated Clinical Course of Crescentic Glomerulonephritis with Positive Anti-Glomerular Basement Membrane Antibodies in a 14-Year-Old Girl.Glomerular diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-glomerular basement membrane disease (Anti-GBM), previously known as Goodpasture syndrome, is an extremely rare cause of rapidly progressive glomerulonephritis and chronic kidney disease stage 5 (CKD5) in children. It is associated with acute pulmonary haemorrhage and it has a poor prognosis. It is classified as an autoimmune, small-vessel vasculitis caused by autoantibody formation against the alpha-3 chain in type IV collagen found in the glomerular basement membrane. Evidence of anti-GBM antibodies in serum or histologically are required for diagnosis. Treatment in children is based on very limited adult data and often involves the use of acute apheresis to rapidly remove circulating factors coupled with intensive immunosuppression such as cyclophosphamide and intravenous corticosteroids. There is also an emerging role for the use of biologic agents such as B cell depletion. The evidence base in children with anti-GBM disease is extremely limited. Multi-centre international collaboration is required to provide insight into this disease, better describe its prognosis and work towards improving outcomes. This review article summarises the key features of this disease in children, highlights treatment options and considers areas of unmet need.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.